Sanofi SA (SNY)

48.07
0.36 0.75
NYSE : Health Care
Prev Close 47.71
Open 48.75
Day Low/High 48.03 / 48.75
52 Wk Low/High 36.81 / 50.24
Volume 914.48K
Avg Volume 1.93M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 123.28B
EPS 1.80
P/E Ratio 25.65
Div & Yield 1.64 (3.40%)

Latest News

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences

Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences

Sanofi was also recently engaged in two other deals that it lost out on.

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Tech, healthcare slide weighs on rest of markets.

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Healthcare's slide weighs on rest of markets.

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

The stock has been on fire.

Looking for Some Positive Spin

Breadth and volume should've been better.

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.

New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c By More Than 2 Percent In Patients With Screening Levels Greater Than 9 Percent

- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -

In Senior Adults Treated With Basal Insulin, Switching To Sanofi's Toujeo® Halved Hypoglycemia Risk

- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports

Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports

The magnetic tape cartridges in the company's products will be under review.

Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks

Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks

The cybersecurity firm deemed it 'highly likely' that a group of hackers working with North Korea was behind the attack.

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

The legislation would also force companies to announce planned price hikes.

Regeneron Shares Rise After Reporting Better-Than-Expected Sales

Regeneron Shares Rise After Reporting Better-Than-Expected Sales

The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

Sarepta Therapeutics May Attract Activist Attention

Sarepta Therapeutics May Attract Activist Attention

Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.

Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round

Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round

Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.

15 Movie Remakes Coming to the Silver Screen in 2017

15 Movie Remakes Coming to the Silver Screen in 2017

Whether you loved the original or not, these sequels are making their way to a theater near you.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

K-Mart to Sell Cheaper EpiPen Alternative

K-Mart to Sell Cheaper EpiPen Alternative

K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.